{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematologic+Disease&page=54",
    "query": {
      "condition": "Hematologic Disease",
      "page": 54
    },
    "page_size": 10
  },
  "pagination": {
    "page": 54,
    "page_size": 10,
    "total_count": 10729,
    "total_pages": 1073,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematologic+Disease&page=55&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematologic+Disease&page=53&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T06:55:09.510Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06998524",
      "title": "A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Von Willebrand Disease, Type 3"
      ],
      "interventions": [
        {
          "name": "Emicizumab",
          "type": "DRUG"
        },
        {
          "name": "von Willebrand Factor (VWF) Concentrates",
          "type": "DRUG"
        },
        {
          "name": "Factor VIII (FVIII) Concentrates",
          "type": "DRUG"
        },
        {
          "name": "von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates",
          "type": "DRUG"
        },
        {
          "name": "Bypassing Agents",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Month and older"
      },
      "enrollment_count": 75,
      "start_date": "2025-06-27",
      "completion_date": "2029-09-06",
      "has_results": false,
      "last_update_posted_date": "2026-11-16",
      "last_synced_at": "2026-11-19T06:55:09.510Z",
      "location_count": 6,
      "location_summary": "Sacramento, California • Gainesville, Florida • Lexington, Kentucky + 3 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06998524"
    },
    {
      "nct_id": "NCT06395103",
      "title": "Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "B-cell Acute Lymphoblastic Leukemia",
        "Diffuse Large B-cell Lymphoma",
        "Burkitt Lymphoma",
        "Neuroblastoma",
        "Ewing Sarcoma"
      ],
      "interventions": [
        {
          "name": "Zilovertamab vedotin",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "6 Months to 25 Years"
      },
      "enrollment_count": 90,
      "start_date": "2024-08-16",
      "completion_date": "2029-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-30",
      "last_synced_at": "2026-11-19T06:55:09.510Z",
      "location_count": 17,
      "location_summary": "Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 14 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06395103"
    },
    {
      "nct_id": "NCT00001561",
      "title": "Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Graft vs Host Disease",
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Myeloma Immunoglobulin Idiotype Vaccine-KLH",
          "type": "DRUG"
        },
        {
          "name": "GM-CSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 30,
      "start_date": "1996-11",
      "completion_date": "2005-09",
      "has_results": false,
      "last_update_posted_date": "2007-09-24",
      "last_synced_at": "2026-11-19T06:55:09.510Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001561"
    },
    {
      "nct_id": "NCT05211570",
      "title": "AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia Refractory",
        "Acute Myeloid Leukemia, in Relapse",
        "Myelodysplastic Syndrome Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "AB8939",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AB Science",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2022-06-01",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-10-02",
      "last_synced_at": "2026-11-19T06:55:09.510Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05211570"
    },
    {
      "nct_id": "NCT00614042",
      "title": "Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia (CLL)",
        "Non-Hodgkin's Lymphoma (NHL)"
      ],
      "interventions": [
        {
          "name": "TRU-016 (anti-CD37 protein therapeutic)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aptevo Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2008-01",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2017-06-28",
      "last_synced_at": "2026-11-19T06:55:09.510Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Augusta, Georgia • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00614042"
    },
    {
      "nct_id": "NCT05401097",
      "title": "IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Enasidenib",
          "type": "DRUG"
        },
        {
          "name": "Ivosidenib",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Alice Mims",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 125,
      "start_date": "2022-09-13",
      "completion_date": "2029-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-11-19T06:55:09.510Z",
      "location_count": 4,
      "location_summary": "Aurora, Colorado • Chapel Hill, North Carolina • Columbus, Ohio + 1 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05401097"
    },
    {
      "nct_id": "NCT06712810",
      "title": "Q702 for the Treatment of Patients With Hematologic Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hematopoietic and Lymphatic System Neoplasm",
        "Histiocytic Sarcoma",
        "Malignant Histiocytosis",
        "Peripheral T-Cell Lymphoma, Not Otherwise Specified",
        "Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Chronic Myelomonocytic Leukemia",
        "Recurrent Follicular Lymphoma",
        "Recurrent Langerhans Cell Histiocytosis",
        "Recurrent Lymphoplasmacytic Lymphoma",
        "Recurrent Myelodysplastic Syndrome",
        "Recurrent Myelofibrosis",
        "Recurrent Small Lymphocytic Lymphoma",
        "Recurrent Waldenstrom Macroglobulinemia",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Chronic Myelomonocytic Leukemia",
        "Refractory Erdheim-Chester Disease",
        "Refractory Follicular Lymphoma",
        "Refractory Langerhans Cell Histiocytosis",
        "Refractory Lymphoplasmacytic Lymphoma",
        "Refractory Myelodysplastic Syndrome",
        "Refractory Myelofibrosis",
        "Refractory Small Lymphocytic Lymphoma",
        "Refractory Waldenstrom Macroglobulinemia",
        "Rosai-Dorfman-Destombes Disease",
        "Primary Central Nervous System Lymphoma",
        "Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm",
        "Recurrent Erdheim-Chester Disease",
        "Recurrent Fibroblastic Reticular Cell Sarcoma",
        "Recurrent Histiocytic Sarcoma",
        "Recurrent Interdigitating Dendritic Cell Sarcoma",
        "Recurrent Rosai-Dorfman-Destombes Disease",
        "Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm",
        "Refractory Fibroblastic Reticular Cell Sarcoma",
        "Refractory Histiocytic Sarcoma",
        "Refractory Interdigitating Dendritic Cell Sarcoma",
        "Refractory Rosai-Dorfman-Destombes Disease"
      ],
      "interventions": [
        {
          "name": "Axl/Mer/CSF1R Inhibitor Q702",
          "type": "DRUG"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2025-08-27",
      "completion_date": "2030-09-15",
      "has_results": false,
      "last_update_posted_date": "2025-10-10",
      "last_synced_at": "2026-11-19T06:55:09.510Z",
      "location_count": 2,
      "location_summary": "Scottsdale, Arizona • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06712810"
    },
    {
      "nct_id": "NCT00128973",
      "title": "Evaluation of Patients With Immune Function Abnormalities",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Granulomatous Disease (CGD)",
        "X-Linked Severe Combined Immune Deficiency (XSCID)",
        "Leukocyte Adhesion Deficiency 1 (LAD)",
        "Graft Versus Host Disease (cGvHD)"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 3500,
      "start_date": "2005-09-19",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-11-09",
      "last_synced_at": "2026-11-19T06:55:09.510Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00128973"
    },
    {
      "nct_id": "NCT00005773",
      "title": "Early Inhaled Nitric Oxide for Respiratory Failure in Newborns",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infant, Newborn",
        "Hypertension, Pulmonary",
        "Persistent Fetal Circulation Syndrome",
        "Pneumonia, Aspiration",
        "Respiratory Distress Syndrome, Newborn",
        "Respiratory Insufficiency"
      ],
      "interventions": [
        {
          "name": "Inhaled Nitric Oxide",
          "type": "DRUG"
        },
        {
          "name": "Standard iNO therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NICHD Neonatal Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "14 Days",
        "sex": "ALL",
        "summary": "Up to 14 Days"
      },
      "enrollment_count": 302,
      "start_date": "1998-08",
      "completion_date": "2003-08",
      "has_results": false,
      "last_update_posted_date": "2017-09-26",
      "last_synced_at": "2026-11-19T06:55:09.510Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005773"
    },
    {
      "nct_id": "NCT00001405",
      "title": "Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells, Mononuclear Cells and Granulocytes",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Granuloma",
        "Granulomatous Disease, Chronic",
        "Leukocyte Disease",
        "Genetic Disease, X-Linked",
        "Genetic Disease, Inborn"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 850,
      "start_date": "1994-02-27",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-11-09",
      "last_synced_at": "2026-11-19T06:55:09.510Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001405"
    }
  ]
}